ArticleGene therapy2010
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.
Article in Gene therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 71 citations in OpenAlex.
- Article
- Viral vector platforms within the gene therapy landscape.Signal transduction and targeted therapy · 2021Review
- Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy.Nanomaterials (Basel, Switzerland) · 2021Article
- Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19.SN comprehensive clinical medicine · 2021Review
- Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy.Cancer gene therapy · 2018Review
- Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.Oncotarget · 2018Article
- Article
- Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles.BMC veterinary research · 2015Article
- Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Pediatric blood & cancer · 2015Article
- Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.Oncoimmunology · 2015Article
- Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.Molecular therapy. Methods & clinical development · 2015Article
- Oncolytic viruses: From bench to bedside with a focus on safety.Human vaccines & immunotherapeutics · 2015Review
- Oncolytic immunotherapy: where are we clinically?Scientifica · 2014Review
- Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles.Molecular therapy oncolytics · 2014Article
- Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.Current gene therapy · 2013Review
- Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia.Oncotarget · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eighteen patients with refractory and progressive solid tumors were treated with a single round of triple modified oncolytic adenovirus (Ad5/3-Cox2L-D24). Ad5/3-Cox2L-D24 is the first non-Coxsackie-adenovirus receptor-binding oncolytic adenovirus used in humans. Grades 1-2 flu-like symptoms, fever, and fatigue were seen in most patients, whereas transaminitis or thrombocytopenia were seen in some. Non-hematological grades 3-5 side effects were seen in one patient with grade 3 ileus. Treatment resulted in high neutralizing antibody titers within 3 weeks. Virus appeared in serum 2-4 days after treatment in 83% of patients and persisted for up to 5 weeks. One out of five radiologically evaluable patients had partial response (PR), one had minor response (MR), and three had progressive disease (PD). Two patients scored as PD had a decrease in tumor density. Tumor reductions not measurable with Response Evaluation Criteria In Solid Tumors (RECIST) were seen in a further four patients. PR, MR, stable disease, and PD were seen in 12, 23.5, 35, and 29.5% of tumor markers analyzed, respectively (N=17). Ad5/3-Cox2L-D24 appears safe for treatment of cancer in humans and extended virus circulation results from a single treatment. Objective evidence of anti-tumor activity was seen in 11/18 (61%) of patients. Clinical trials are needed to extend these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.